Why the study?
Do prothrombin complex concentrates (PCCs) and activated PCCs (aPCCs) reverse dabigatran-induced anticoagulation in patients requiring emergency reversal?
Do prothrombin complex concentrates (PCCs) and activated PCCs (aPCCs) reverse dabigatran-induced anticoagulation in patients requiring emergency reversal?
The use of PCCs and aPCCs appears warranted for dabigatran reversal in patients with life-threatening haemorrhage if the specific reversal agent idarucizumab is unavailable.
No takes yet. Share an insight, caveat, or question.
Idarucizumab enables targeted dabigatran reversal in emergencies; leaves open optimal selection versus PCCs.
Grottke et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: